Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.35 |
| ▸ | ESR1 | P03372 | 7/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815280 | 0.88 | ESR2 (0.37) | ESR2ESR1CYP26A1CYP26B1 | |
| SCHEMBL17539089 | 0.78 | ESR2 (0.35) | ESR2ESR1 | |
| SCHEMBL6399115 | 0.78 | KDM4E (0.35) | KDM4EALDH1A1ALOX5GAAMAPT | |
| SCHEMBL4810769 | 0.76 | PDK2 (0.33) | ESR2ESR1PDK2 | |
| SCHEMBL17509607 | 0.74 | CYP26A1 (0.37) | ALDH1A1GAAESR2ESR1PDK2 | |
| SCHEMBL4817625 | 0.72 | KDM1A (0.40) | BACE1 | |
| SCHEMBL8733215 | 0.71 | ESR1 (0.39) | KDM4EALDH1A1ALOX5GAAMAPT | |
| SCHEMBL8853672 | 0.69 | ALDH1A1 (0.48) | KDM4EALDH1A1ALOX5GAAMAPT | |
| SCHEMBL17509598 | 0.69 | ALDH1A1 (0.36) | KDM4EALDH1A1GAAMAPTCYP26A1 | |
| SCHEMBL11949124 | 0.68 | KDM4E (0.40) | KDM4EALDH1A1ALOX5GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | KDM4E 1449/4885ALDH1A1 3901/4885ALOX5 3815/4885 |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | KDM4E 2898/4885ALDH1A1 3848/4885ALOX5 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.